David J Askenazi1, Patrick J Heagerty2, Robert H Schmicker2, Patrick Brophy3, Sandra E Juul4, Stuart L Goldstein5, Sangeeta Hingorani4. 1. Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL. Electronic address: daskenazi@peds.uab.edu. 2. University of Washington, Seattle, WA. 3. University of Rochester/Golisano Children's Hospital, Rochester, NY. 4. Department of Pediatrics, University of Washington/Seattle Children's Hospital, Seattle, WA. 5. Department of Pediatrics, Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Cincinnati, OH.
Abstract
OBJECTIVE: To evaluate whether extremely low gestational age neonates (ELGANs) randomized to erythropoietin have better or worse kidney-related outcomes during hospitalization and at 22-26 months of corrected gestational age (cGA) compared with those randomized to placebo. STUDY DESIGN: We performed an ancillary study to a multicenter double-blind, placebo-controlled randomized clinical trial of erythropoietin in ELGANs. RESULTS: The prevalence of severe (stage 2 or 3) acute kidney injury (AKI) was 18.2%. We did not find a statistically significant difference between those randomized to erythropoietin vs placebo for in-hospital primary (severe AKI) or secondary outcomes (any AKI and serum creatinine/cystatin C values at days 0, 7, 9, and 14). At 22-26 months of cGA, 16% of the cohort had an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2, 35.8% had urine albumin/creatinine ratio >30 mg/g, 23% had a systolic blood pressure (SBP) >95th percentile for age, and 40% had a diastolic blood pressure (DBP) >95th percentile for age. SBP >90th percentile occurred less often among recipients of erythropoietin (P < .04). This association remained even after controlling for gestational age, site, and sibship (aOR 0.6; 95% CI 0.39-0.92). We did not find statistically significant differences between treatment groups in eGFR, albumin/creatinine ratio, rates of SBP >95th percentile, or DBP >90th or >95th percentiles at the 2 year follow-up visit. CONCLUSIONS: ELGANs have high rates of in-hospital AKI and kidney-related problems at 22-26 months of cGA. Recombinant erythropoietin may protect ELGANs against long-term elevated SBP but does not appear to protect from AKI, low eGFR, albuminuria, or elevated DBP at 22-26 months of cGA.
OBJECTIVE: To evaluate whether extremely low gestational age neonates (ELGANs) randomized to erythropoietin have better or worse kidney-related outcomes during hospitalization and at 22-26 months of corrected gestational age (cGA) compared with those randomized to placebo. STUDY DESIGN: We performed an ancillary study to a multicenter double-blind, placebo-controlled randomized clinical trial of erythropoietin in ELGANs. RESULTS: The prevalence of severe (stage 2 or 3) acute kidney injury (AKI) was 18.2%. We did not find a statistically significant difference between those randomized to erythropoietin vs placebo for in-hospital primary (severe AKI) or secondary outcomes (any AKI and serum creatinine/cystatin C values at days 0, 7, 9, and 14). At 22-26 months of cGA, 16% of the cohort had an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73 m2, 35.8% had urine albumin/creatinine ratio >30 mg/g, 23% had a systolic blood pressure (SBP) >95th percentile for age, and 40% had a diastolic blood pressure (DBP) >95th percentile for age. SBP >90th percentile occurred less often among recipients of erythropoietin (P < .04). This association remained even after controlling for gestational age, site, and sibship (aOR 0.6; 95% CI 0.39-0.92). We did not find statistically significant differences between treatment groups in eGFR, albumin/creatinine ratio, rates of SBP >95th percentile, or DBP >90th or >95th percentiles at the 2 year follow-up visit. CONCLUSIONS: ELGANs have high rates of in-hospital AKI and kidney-related problems at 22-26 months of cGA. Recombinant erythropoietin may protect ELGANs against long-term elevated SBP but does not appear to protect from AKI, low eGFR, albuminuria, or elevated DBP at 22-26 months of cGA.
Authors: D S Souza; D M Spencer; T S I Salles; M A Salomão; E Payen; Y Beuzard; H F Carvalho; F F Costa; S T Olalla Saad Journal: Braz J Med Biol Res Date: 2010-05-21 Impact factor: 2.590
Authors: David J Askenazi; Patrick J Heagerty; Robert H Schmicker; Russell Griffin; Patrick Brophy; Sandra E Juul; Dennis E Mayock; Stuart L Goldstein; Sangeeta Hingorani Journal: Pediatr Nephrol Date: 2020-06-02 Impact factor: 3.714
Authors: Sarah L White; Vlado Perkovic; Alan Cass; Choon Lan Chang; Neil R Poulter; Tim Spector; Leigh Haysom; Jonathan C Craig; Isa Al Salmi; Steven J Chadban; Rachel R Huxley Journal: Am J Kidney Dis Date: 2009-04-01 Impact factor: 8.860
Authors: George J Schwartz; Michael F Schneider; Paula S Maier; Marva Moxey-Mims; Vikas R Dharnidharka; Bradley A Warady; Susan L Furth; Alvaro Muñoz Journal: Kidney Int Date: 2012-08 Impact factor: 10.612
Authors: Sangeeta Hingorani; Robert Schmicker; Kaashif A Ahmad; Ivan D Frantz; Dennis E Mayock; Edmund F La Gamma; Mariana Baserga; Janine Y Khan; Maureen M Gilmore; Tonya Robinson; Patrick Brophy; Patrick J Heagerty; Sandra E Juul; Stuart Goldstein; David Askenazi Journal: Clin J Am Soc Nephrol Date: 2022-07-19 Impact factor: 10.614
Authors: Sangeeta Hingorani; Robert H Schmicker; Patrick D Brophy; Patrick J Heagerty; Sandra E Juul; Stuart L Goldstein; David Askenazi Journal: Clin J Am Soc Nephrol Date: 2021-06-11 Impact factor: 10.614